Oral delivery of particulate prostate cancer vaccine: In vitro and in vivo evaluation
Oral delivery of particulate prostate cancer vaccine: In vitro and in vivo evaluation
复制标题
DOI：
10.3109/1061186x.2011.654122
复制
发表时间：
2012-05-01
影响因子：
4.5
通讯作者：
D'Souza, Martin J.
中科院分区：
文献类型：
--
作者：
Akalkotkar, Archana;Tawde, Suprita A.;D'Souza, Martin J.
背景：已经评估了用于产生针对肿瘤抗原的有效免疫应答的各种方法。我们的方法利用微粒递送产生针对前列腺癌antigens.Purpose的免疫应答：本研究的目的是评估来自小鼠前列腺癌细胞系TRAMP C2的前列腺癌疫苗在小鼠模型中通过口服途径的功效，所述口服途径使用橙色糊粉菌凝集素作为肠派尔集合淋巴结中M细胞的靶向配体。从TRAMP C2鼠前列腺癌细胞系获得全细胞裂解物（WCL），并使用一步喷雾干燥方法将其配制成颗粒。对于体内研究，每两周一次口服接种4-6周龄C57 BL/6雄性小鼠，持续10周。定期分析血清样品以确定血清IgG水平。结果：免疫组小鼠血清IgG水平明显高于对照组。结论：口服微粒WCL疫苗可诱导机体产生抗前列腺癌抗原的免疫应答。
Background: Various approaches have been evaluated for generation of efficient immune response against tumor antigens. Our approach exploits usage of particulate delivery to generate immune response against prostate cancer antigens.Purpose: The aim of this study was to evaluate the efficacy of prostate cancer vaccine derived from a murine prostate cancer cell line, TRAMP C2 in murine model via oral route using aleuria aurantia lectin as a targeting ligand for M-cells in the intestinal Peyer's patches.Methods: The whole cell lysate (WCL) was obtained from TRAMP C2 murine prostate cancer cell line and was formulated into particles using one step spray drying process. For in vivo studies, 4-6 week old C57BL/6 male mice were vaccinated orally biweekly for 10 weeks. Serum samples were analyzed at regular intervals to determine serum IgG levels. The mice were then challenged with live TRAMP C2 cells to determine efficacy of the vaccine.Results: The serum IgG levels of vaccinated animals were higher compared to that of the controls. Moreover, the tumor growth was retarded significantly in the vaccinated mice compared to that of controls (p < 0.001).Conclusions: The above findings suggest that oral particulate WCL vaccine can trigger an immune response against prostate cancer antigens.